Comprehensive Analysis of eRNAs and Genes Involved in Gastric Cancer and Constructing a Prognostic Model Predicting the Overall Survival of Patients

Document Type : Original Article(s)

Authors

1 MSc, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Gastric cancer (GC) is one of the most prevalent cancers and the first cause of cancer-related deaths in Iran. These patients are diagnosed at advanced stages, which leads to poor prognosis because there is inadequate knowledge of molecular factors to provide diagnostic/prognostic biomarkers. The aim of the current study was the comprehensive analysis of enhancer RNAs (eRNAs) to determine their molecular interactions with other genes and propose a survival-related model for patients.
Methods: RNA-sequencing raw data of GC patients were downloaded from The Cancer Genome Atlas (TCGA), and differentially-expressed eRNAs and genes in tumors compared to non-tumor samples were extracted. The target genes of each eRNA were then identified based on physical distance, correlation, and a regulatory network was constructed with these elements. A prognostic model for predicting the overall survival of patients was eventually established by performing univariate and multivariate Cox regression analyses, and the performance of the model was surveyed.
Findings: By performing differential expression analysis, 69 and 2606 differentially-expressed eRNAs and genes were extracted, respectively, and by identifying the relationships between these elements, a regulatory network consisting of 84 nodes and 119 edges was constructed. A three-components survival-related model subsequently was established which could predict patients' outcomes.
Conclusion: Based on the results, the 3-component constructed model, including an eRNA and two other genes, can be considered as a possible prognostic tool; however, further research is needed to clinically implement it.

Keywords

Main Subjects

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
  2. Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020; 39(4): 1179-203.
  3. Ding M, Liu Y, Liao X, Zhan H, Liu Y, Huang W. Enhancer RNAs (eRNAs): New insights into gene transcription and disease treatment. J Cancer 2018; 9(13): 2334-40.
  4. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn) 2015; 19(1A): A68-77.
  5. Gu X, Wang L, Boldrup L, Coates PJ, Fahraeus R, Sgaramella N, et al. Ap001056.1, a prognosis-related enhancer rna in squamous cell carcinoma of the head and neck. Cancers (Basel) 2019; 11(3): 347.
  6. Zhang Z, Lee JH, Ruan H, Ye Y, Krakowiak J, Hu Q, et al. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nat Commun 2019; 10(1): 4562.
  7. Ang X, Xu Z, Zhou Q, Zhang Z, Ma L, Zhang X, et al. PARGP1, a specific enhancer RNA associated with biochemical recurrence of prostate cancer. All Life 2021; 14(1): 774-81.
  8. Guo XY, Zhong S, Wang ZN, Xie T, Duan H, Zhang JY, et al. Immunogenomic profiling demonstrate AC003092. 1 as an immune-related eRNA in glioblastoma multiforme. Front Genet 2021; 12: 633812.
  9. Zhang Y, Yan Y, Ning N, Shen Z, Ye Y. WAKMAR2, a prognosis-related enhancer RNA in gastric cancer; 2020.
  10. Yang S, Zou X, Yang H, Li J, Zhang A, Zhang L, et al. Identification of enhancer RNA CDK6-AS1 as a potential novel prognostic biomarker in gastric cancer. Front Genet 2022; 13: 854211.
  11. Khalafiyan A, Emadi-Baygi M, Wolfien M, Salehzadeh-Yazdi A, Nikpour P. Construction of a three-component regulatory network of transcribed ultraconserved regions for the identification of prognostic biomarkers in gastric cancer. J Cell Biochem 2023; 124(3): 396-408.
  12. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Čech M, et al. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res 2018; 46(W1): W537-44.
  13. Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. Nucleic Acids Res 2020; 48(D1): D682-8.
  14. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15(12): 550.
  15. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30(7): 923-30.
  16. R Development Core Team. R: A language and environment for statistical computing; 2013.
  17. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13(11): 2498-504.
  18. Therneau TM, Lumley T. Package ‘survival’. R Top Doc 2015; 128(10): 28-33.
  19. Heagerty PJ, Saha-Chaudhuri P, Saha-Chaudhuri MP. Package ‘survivalROC’. San Fr GitHub; 2013.
  20. Ripley B, Venables B, Bates DM, Hornik K, Gebhardt A, Firth D, et al. Package ‘mass’. Cran r 2013; 538: 113-20.
  21. Wickham H. ggplot2. Wiley Interdiscip Rev Comput Stat 2011; 3(2): 180-5.
  22. Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options. Am Fam Physician 2004; 69(5): 1133-40.
  23. Liu GX, Tan YZ, He GC, Zhang QL, Liu P. EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer. Medicine (Baltimore) 2021; 100(41): e27535.
  24. Ren W, Zhang J, Li W, Li Z, Hu S, Suo J, et al. A tumor-specific prognostic long non-coding RNA signature in gastric cancer. Med Sci Monit 2016; 22: 3647.
  25. Wang W, He X, Wang Y, Liu H, Zhang F, Wu Z, et al. LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer. Cancer Sci 2022; 113(8): 2484-95.
  26. Wang H, Wu M, Lu Y, He K, Cai X, Yu X, et al. LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling. Aging (Albany NY) 2019; 11(17): 6657-73.
  27. Gao LF, Li W, Liu YG, Zhang C, Gao WN, Wang L. Inhibition of MIR4435-2HG on invasion, migration, and EMT of gastric carcinoma cells by mediating MiR-138-5p/Sox4 axis. Front Oncol 2021; 11: 661288.
  28. Shen D, Zhang Y, Zheng Q, Yu S, Xia L, Cheng S, et al. A competing endogenous RNA network and an 8-lncRNA prognostic signature identify MYO16-AS1 as an oncogenic lncRNA in bladder cancer. DNA Cell Biol 2021; 40(1): 26-35.
Journal of Isfahan Medical School
Volume 41, Issue 724
4th Week, August
July and August 2023
Pages 488-495

Files

History

  • Receive Date: 28 May 2023
  • Accept Date: 11 June 2023

Share

How to cite

Statistics